1. Introduction {#sec1}
===============

With its highest incidences in Asia---especially in China---and Eastern Europe, cerebral infarction remains a global concern. Moreover, according to the European Stroke Burden Report, no changes in the current incidence of cerebral infarctions will increase the total number of stroke events by more than 30% between 2015 and 2035 \[[@B1], [@B2]\]. However, the mechanism underlying the onset of cerebral infarction remains to be elucidated. Most studies of cerebral infarction have focused on its treatment and prognosis \[[@B3]\]. Some studies suggest that the neuroendocrine status is related to the prognosis of patients with acute cerebral infarction \[[@B4]\]. Patients with severe neuroendocrine disorders have a poor prognosis. Studies have shown that serum uric acid (UA), a metabolite of purine \[[@B5]\], can predict cardiovascular and cerebrovascular accidents and is associated with early changes in neurological function. A meta-analysis found that high serum UA levels had a neuroprotective effect on the prognosis of patients with acute ischemic stroke \[[@B6]\]. However, the relationship between UA and cerebral infarction is still controversial. While some research has shown that UA is involved in the formation of cerebral atherosclerosis, is a risk factor for cerebral infarction, and can cause cardiovascular and cerebrovascular accidents \[[@B7], [@B8]\], a study has shown that serum UA has no relationship to cerebral infarction \[[@B9]\]. To help resolve this controversy, the present study investigated whether UA levels at admission were independently associated with the severity of acute primary cerebral infarction.

2. Materials and Methods {#sec2}
========================

2.1. Research Design {#sec2.1}
--------------------

This cross-sectional study explored the relationship between UA and the severity of acute primary cerebral infarction. The level of serum UA at the time of admission was selected as the independent variable and the degree of neurological impairment at admission as the dependent variable.

2.2. Research Population {#sec2.2}
------------------------

We collected baseline data from patients who were hospitalized in the Department of Neurology, the First People\'s Hospital of Changde City, from November 1, 2018, to August 31, 2019. The criteria for inclusion in this study were as follows: (1) incidence time \< 48 hours and (2) an acute cerebral infarction that was confirmed by MRI during hospitalization. Exclusion criteria were as follows: (1) a history of cerebral infarction, malignant tumor, gouty arthritis, kidney disease, systemic infection, or an autoimmune disease; (2) the recent intake of drugs related to UA metabolism; and (3) missing data. All data were obtained from the participating hospital\'s electronic medical record system.

2.3. Method for Measuring the Degree of Neurological Dysfunction {#sec2.3}
----------------------------------------------------------------

The National Institutes of Health Stroke Scale (NIHSS) was used to assess the extent of neurological dysfunction. The NIHSS value was assessed and recorded by a neurologist at the time of admission. An NIHSS score of ≤5 was considered to indicate a minor stroke; NIHSS scores of \>5, moderate to severe stroke \[[@B10]--[@B12]\].

2.4. Measurement of UA {#sec2.4}
----------------------

The specific process of UA measurement was as follows: (1) Venous blood was collected on the first day of the patient\'s admission and sent to the laboratory through our hospital\'s transportation system. (2) UA activity was measured using an oxidase method UA kit, the performance of which was approved by the national testing agency.

2.5. Statistical Analysis {#sec2.5}
-------------------------

We represent continuous variables in two ways. The continuous distribution of normal variables is expressed as the mean ± standard deviation, while skewed distributions are expressed as medians and interquartile ranges (Q1-Q3). Classification variables are expressed in terms of frequency or percentage. We used a one-way analysis of variance (normal distribution), the Kruskal-Wallis H (skewed distribution) test, and the chi-square test (categorical variables) to examine differences between different UA groups. Our method of data analysis can be divided into two steps. In the first step, we explored the linear relationship between UA and NIHSS by using three linear regression models: Model 1, without covariate adjustments; Model 2, adjusted for social demographic data only, including age and sex; and Model 3, adjusted for all the covariates shown in [Table 1](#tab1){ref-type="table"}. In the second step, we explored the nonlinear relationship between UA and NIHSS and performed a smooth curve fit. If nonlinearity was detected, we first calculated the inflection point using a recursive algorithm and then constructed a two-stage linear regression on both sides. The optimal fit model was determined based on the log likelihood ratio test value. To ensure the robustness of the data analysis, we conducted a sensitivity analysis. We converted the UA into a categorical variable and calculated the *P* value of the trend. The purpose of the test was to verify the results of treating UA as a continuous variable and to determine the possibility of nonlinearity. All the analyses were performed with the statistical software package R (<http://www.R-project.org>, the R Foundation) and EmpowerStats (<http://www.empowerstats.com>, X&Y Solutions, Inc., Boston, MA). *P* values of \<0.05 (both sides) were considered statistically significant.

3. Results {#sec3}
==========

3.1. Participant Selection {#sec3.1}
--------------------------

Based on our strict screening criteria, a total of 238 patients were selected for final data analysis. A total of 51 were excluded, including 10 patients with a history of kidney disease, two patients with a history of cancer, and 39 patients with an onset time of more than 48 hours (see [Figure 1](#fig1){ref-type="fig"} for a flow chart).

3.2. Baseline Characteristics of Participants {#sec3.2}
---------------------------------------------

The baseline data characteristics of the patients are shown in [Table 2](#tab2){ref-type="table"}. The average age of the 238 subjects was 64.41 ± 10.76 years, 65.97% of whom were men. There was statistically significant difference in triglyceride, creatinine, homocysteine, sex, smoking, and NIHSS across quartiles of UA (all *P* \< 0.05), but no difference in age, systolic blood pressure, diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, urea nitrogen, history of hypertension, history of coronary heart disease, history of diabetes, and drinking (all *P* \> 0.05).

3.3. Univariate Analysis of the Degree of Neurological Dysfunction {#sec3.3}
------------------------------------------------------------------

The results of the univariate analysis are listed in [Table 3](#tab3){ref-type="table"}. The univariate analysis showed that sex; systolic blood pressure; diastolic blood pressure; histories of hypertension, diabetes, smoking, and drinking; total cholesterol; triglyceride; high-density lipoprotein; low-density lipoprotein; homocysteine; and creatinine were not associated with NIHSS. Age, urea nitrogen, and history of coronary heart disease were positively correlated with NIHSS, while UA negatively correlated with NIHSS.

3.4. The Relationship between UA and NIHSS according to Three Linear Regression Models {#sec3.4}
--------------------------------------------------------------------------------------

The results obtained from the adjusted and unadjusted models are presented in [Table 1](#tab1){ref-type="table"}, which reveals that UA raw data and UA increased by 10 *μ*mol/L. The finding can be explained as follows: the use of the unadjusted model (crude model) indicated an 8% reduction in the risk of moderate to severe cerebral infarction (OR 0.92, 95% CI 0.88 to 0.95, *P* \< 0.0001) for every 10 *μ*mol/L increase in UA. In the minimal adjustment model (Model I), the results were interpreted as an 8% reduction in the risk of moderate to severe cerebral infarction (OR 0.92, 95% CI 0.89 to 0.95, *P* \< 0.0001) for every 10 *μ*mol/L increase in UA. Finally, after we completely adjusted the variables (Model II), the results could be explained by a 9% increase in the risk of moderate to severe cerebral infarction for each UA increase of 10 *μ*mol/L (OR 0.91, 95% CI 0.87 to 0.95, *P* \< 0.0001). For the sensitivity analysis, we also treated UA as a quarantine (quartile) and observed the same trend. As UA concentration increased, the risk of moderate to severe cerebral infarction decreased.

3.5. The Analyses of Nonlinear Relationships {#sec3.5}
--------------------------------------------

This study found a nonlinear relationship between UA and NIHSS (adjusted sex, age, systolic blood pressure, diastolic blood pressure, hypertension, diabetes, coronary artery disease, smoking, alcohol consumption, total cholesterol, triglycerides, high-density lipoprotein cholesterol, LDL cholesterol, homocysteine, creatinine, and urea nitrogen; [Figure 2](#fig2){ref-type="fig"}). Through the two-segment linear regression model, the inflection point was calculated to be 372 *μ*mol/L, and the influence and confidence intervals of the left and right sides of the inflection point were determined to be 0.99 (0.98, 0.99) and 1.00 (1.00, 1.01) ([Table 4](#tab4){ref-type="table"}), respectively.

4. Discussion {#sec4}
=============

This study suggested that when UA was \<372 *μ*mol/L, UA was negatively correlated with the degree of neurological damage in patients with acute cerebral infarction. Yang et al. \[[@B13]\] found UA concentration to be negatively correlated with NIHSS scores. Two animal experiments found that treatment with UA after cerebral ischemia could maintain a high perfusion state and reduce nerve damage \[[@B14], [@B15]\]. Chiquete et al. \[[@B16]\] posited that the correlation between low concentration of UA and severity of acute cerebral infarction could be used as a marker of the degree of cerebral infarction. According to Arevalo-Lorido et al. \[[@B17]\], NIHSS scores decrease with increasing UA, even in patients with cerebral infarction and abnormal renal function. In performing a randomized, double-blind, placebo-controlled phase 2b/3 trial in which UA was added during thrombolytic therapy administered to patients with acute cerebral infarction, Chamorro et al. \[[@B18]\] found that UA had a protective effect on the patient\'s nerve function. However, other studies have yielded different results. Sarfo et al. \[[@B19]\] found that UA concentration was positively correlated with the severity of cerebral infarction and positively correlated with early mortality in patients with acute cerebral infarction. Chen et al. \[[@B20]\] found that serum UA level was not significantly correlated with the prognosis of patients with cerebral infarction. The wide variability in these reports can be attributed to different selected outcome indicators, research populations, and research types. Hence, comparisons among these findings are difficult.

The neuroprotective effects of UA can be explained in the following ways: (1) UA has an antioxidative effect, preventing the cerebrovascular system from being damaged by oxidative stress \[[@B21], [@B22]\]. (2) UA can remove oxidative free radicals caused by chelation of metal ions and increase the metabolism of purine in the brain \[[@B23]\]. (3) UA protects local cerebral blood supply by activating the expression of neurotrophic factors and reduces brain damage caused by reperfusion \[[@B24], [@B25]\]. It has been suggested in the literature that UA is an endogenous antioxidant and that low levels of UA are associated with the increased prevalence of neurodegenerative and inflammatory diseases of the central nervous system and deterioration of clinical processes. UA is rapidly consumed after acute cerebral infarction, and high levels of UA are associated with better prognoses \[[@B26]\]. This observation is consistent with our research conclusions.

Many previous studies have revealed a relationship between UA and the severity of cerebral infarction, and our study provides supporting evidence for the protective effect of UA on nerve function in patients with acute cerebral infarction. In this study, the nonlinear relationship between UA and the severity of cerebral infarction was determined, curve fitting was carried out, and the inflection point was calculated. The results were intuitive. It was found that a correlation remains, despite the adjustment of many confounding factors. A meta-analysis of 12739 patients with acute cerebral infarction suggested that, for patients with acute cerebral infarction, high levels of UA at onset have neuroprotective effects and are markers of a better prognosis, especially for patients undergoing thrombolytic therapy, regardless of the type of thrombolytic therapy \[[@B6]\]. This is basically consistent with the results of our study. It is necessary to consider whether patients with cerebral infarction treated with thrombolytic therapy could be given UA supplement, maintaining the upper limit of serum UA \< 372 *μ*mol/L, to minimize neurological damage. In particular, UA supplementation may have greater clinical significance in patients with acute episodes who cannot be treated with thrombolytic therapy. This will be our next research direction.

This study also has several limitations: (1) It was small, mainly comprising patients with acute primary cerebral infarction, and all participants were Chinese. (2) As a cross-sectional study, it could not provide evidence of causality. Large prospective cohort studies are needed to investigate this. (3) Previous studies have shown that UA may be related to the size, type, and location of cerebral infarction \[[@B5], [@B27]\]. Studies have suggested that UA levels may be associated with secondary epilepsy following cerebral infarction \[[@B28]\], but these data were not collected in this study. (4) Patients with cerebral infarction may also have Parkinson\'s disease, decreased cognitive function, or other chronic diseases, which may also be related to UA levels. Due to the limitations of the original data, this avenue of research could not be further explored \[[@B29]--[@B31]\].

5. Conclusion {#sec5}
=============

There was a nonlinear relationship between the UA level measured on admission and the degree of neurological impairment in patients with acute primary cerebral infarction. When UA was \<372 *μ*mol/L, it was negatively correlated with the degree of neurological impairment in patients with acute cerebral infarction, but when UA was ≥372 *μ*mol/L, the protective effect of UA disappeared.
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![Relationship between UA (*μ*mol/L) and NIHSS. The middle line represents a smooth curve fit between the variables. The curves on both sides represent the 95% confidence interval for the fit. The model was adjusted according to sex, age, systolic BP, diastolic BP, hypertension, diabetes, coronary artery disease, smoking, drinking, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, homocysteine, creatinine, and urea nitrogen.](BMRI2020-2310307.002){#fig2}

###### 

Relationship between UA and NIHSS in different models.

  Variable           Crude model         Model I    Model II                                           
  ------------------ ------------------- ---------- ------------------- ---------- ------------------- ----------
  UA (*μ*mol/L)      0.99 (0.99, 0.99)   \<0.0001   0.99 (0.99, 1.00)   \<0.0001   0.99 (0.99, 0.99)   \<0.0001
  UA (10 *μ*mol/L)   0.92 (0.88, 0.95)   \<0.0001   0.92 (0.89, 0.95)   \<0.0001   0.91 (0.87, 0.95)   \<0.0001
  UA (quartile)                                                                                        
   Q1                Reference                      Reference                      Reference           
   Q2                0.44 (0.21, 0.94)   0.0337     0.46 (0.21, 0.98)   0.0452     0.44 (0.18, 1.04)   0.0602
   Q3                0.13 (0.05, 0.34)   \<0.0001   0.14 (0.05, 0.35)   \<0.0001   0.13 (0.04, 0.37)   0.0002
   Q4                0.15 (0.06, 0.37)   \<0.0001   0.17 (0.07, 0.42)   0.0001     0.14 (0.05, 0.42)   0.0004
  *P* for trend                          \<0.0001                       \<0.0001                       \<0.0001

Abbreviations: CI: confidence interval. Model I adjusted for sex and age; Model II adjusted for sex, age, systolic BP, diastolic BP, hypertension, diabetes, coronary artery disease, smoking, drinking, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, homocysteine, creatinine, and urea nitrogen.

###### 

Baseline characteristics of the participants (*N* = 238).

  Characteristic                              UA quartiles (*μ*mol/L)   *P* value                                                          
  ------------------------------------------- ------------------------- --------------------- --------------------- ---------------------- ---------
  No. of participants                         58                        59                    57                    64                     
  Age (years, median, Q1-Q3)                  67.50 (56.25-73.75)       64.00 (55.00-74.00)   65.00 (57.00-71.00)   62.00 (53.00-69.00)    0.182
  Systolic BP (mmHg, mean ± sd)               160.71 ± 25.80            155.22 ± 22.96        155.47 ± 20.47        161.81 ± 23.60         0.271
  Diastolic BP (mmHg, median, Q1-Q3)          86.00 (78.25-98.75)       85.00 (78.00-95.50)   84.00 (78.00-94.00)   88.00 (79.00-100.25)   0.266
  Total cholesterol (mmol/L, median, Q1-Q3)   4.50 (3.87-5.00)          4.64 (4.21-5.37)      4.48 (4.20-4.93)      4.80 (4.08-5.40)       0.521
  Triglyceride (mmol/L, median, Q1-Q3)        1.39 (0.98-1.99)          1.44 (1.11-1.97)      1.80 (1.21-2.45)      1.67 (1.36-2.76)       0.009
  HDL cholesterol (mmol/L, median, Q1-Q3)     1.12 (0.93-1.31)          1.09 (0.94-1.28)      1.02 (0.91-1.15)      1.03 (0.95-1.17)       0.107
  LDL cholesterol (mmol/L, median, Q1-Q3)     2.51 (2.09-3.20)          2.60 (2.25-3.40)      2.64 (2.39-2.98)      2.70 (2.25-3.21)       0.772
  Creatinine (*μ*mol/L, median, Q1-Q3)        66.00 (54.00-75.00)       69.00 (60.00-85.00)   76.00 (67.00-88.00)   87.50 (70.00-104.00)   \<0.001
  Urea nitrogen (*μ*mol/L, median, Q1-Q3)     5.42 (4.56-6.46)          5.45 (4.59-6.32)      5.51 (4.41-6.45)      5.33 (4.39-6.37)       0.944
  Homocysteine (*μ*mol/L, median, Q1-Q3)      11.64 (8.90-14.28)        12.00 (9.87-14.61)    12.91 (10.40-15.30)   13.05 (10.87-16.91)    0.015
  Sex (*n*, %)                                                                                                                             \<0.001
  Male                                        27 (46.55%)               38 (64.41%)           39 (68.42%)           53 (82.81%)            
  Female                                      31 (53.45%)               21 (35.59%)           18 (31.58%)           11 (17.19%)            
  Hypertension (*n*, %)                                                                                                                    0.337
   No                                         25 (43.10%)               24 (40.68%)           16 (28.07%)           26 (40.62%)            
   Yes                                        33 (56.90%)               35 (59.32%)           41 (71.93%)           38 (59.38%)            
  Diabetes (*n*, %)                                                                                                                        0.994
   No                                         49 (84.48%)               50 (84.75%)           48 (84.21%)           55 (85.94%)            
   Yes                                        9 (15.52%)                9 (15.25%)            9 (15.79%)            9 (14.06%)             
  Coronary artery disease (*n*, %)                                                                                                         0.096
   No                                         46 (79.31%)               54 (91.53%)           53 (92.98%)           57 (89.06%)            
   Yes                                        12 (20.69%)               5 (8.47%)             4 (7.02%)             7 (10.94%)             
  Smoking (*n*, %)                                                                                                                         0.013
   No                                         45 (77.59%)               44 (74.58%)           35 (61.40%)           34 (53.12%)            
   Yes                                        13 (22.41%)               15 (25.42%)           22 (38.60%)           30 (46.88%)            
  Drinking (*n*, %)                                                                                                                        0.111
   No                                         53 (91.38%)               44 (74.58%)           46 (80.70%)           50 (78.12%)            
   Yes                                        5 (8.62%)                 15 (25.42%)           11 (19.30%)           14 (21.88%)            
  NIHSS                                                                                                                                    \<0.001
  Minor stroke (NIHSS ≤ 5)                    28 (48.28%)               40 (67.80%)           50 (87.72%)           55 (85.94%)            
  Moderate to severe stroke (NIHSS \> 5)      30 (51.72%)               19 (32.20%)           7 (12.28%)            9 (14.06%)             

Note: the continuous variable of nonnormal distribution is calculated by Kruskal-Wallis H test. BP: blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; UA: uric acid; NIHSS: National Institutes of Health Stroke Scale.

###### 

Univariate analysis for NIHSS.

  Covariate                          Statistics       OR (95% CI)          *P* value
  ---------------------------------- ---------------- -------------------- -----------
  Sex (*n*, %)                                                             
   Male                              157 (65.97%)     Ref                  
   Female                            81 (34.03%)      1.71 (0.95, 3.08)    0.0726
  Age (years)                        64.41 ± 10.75    1.04 (1.01, 1.07)    0.0064
  Systolic BP (mmHg)                 158.39 ± 23.35   0.99 (0.98, 1.00)    0.2146
  Diastolic BP (mmHg)                87.84 ± 15.03    0.99 (0.97, 1.01)    0.2367
  Hypertension (*n*, %)                                                    
   No                                91 (38.24%)      Ref                  
   Yes                               147 (61.76%)     0.76 (0.42, 1.35)    0.3468
  Diabetes (*n*, %)                                                        
   No                                202 (84.87%)     Ref                  
   Yes                               36 (15.13%)      1.88 (0.90, 3.95)    0.0940
  Coronary artery disease (*n*, %)                                         
   No                                210 (88.24%)     Ref                  
   Yes                               28 (11.76%)      5.22 (2.29, 11.89)   \<0.0001
  Smoking (*n*, %)                                                         
   No                                158 (66.39%)     Ref                  
   Yes                               80 (33.61%)      0.62 (0.33, 1.17)    0.1373
  Drinking (*n*, %)                                                        
   No                                193 (81.09%)     Ref                  
   Yes                               45 (18.91%)      0.83 (0.39, 1.76)    0.6321
  Total cholesterol (mmol/L)         4.70 ± 1.02      0.89 (0.67, 1.18)    0.4218
  Triglyceride (mmol/L)              1.94 ± 1.25      0.72 (0.53, 0.96)    0.0528
  HDL cholesterol (mmol/L)           1.10 ± 0.25      2.09 (0.68, 6.48)    0.2002
  LDL cholesterol (mmol/L)           2.74 ± 0.80      0.91 (0.63, 1.32)    0.6152
  Homocysteine (*μ*mol/L)            13.90 ± 7.82     0.97 (0.92, 1.02)    0.2616
  Creatinine (*μ*mol/L)              78.90 ± 28.88    1.01 (1.00, 1.01)    0.2593
  Urea nitrogen (*μ*mol/L)           5.64 ± 1.94      1.23 (1.06, 1.43)    0.0079
  UA (*μ*mol/L)                      328.87 ± 98.78   0.99 (0.99, 0.99)    \<0.0001

Abbreviations: CI: confidence interval; OR: odds ratio.

###### 

Univariate analysis for NHISS.

  Inflection point of UA   Effect size (OR)   95% CI *P* value   *P* value
  ------------------------ ------------------ ------------------ -----------
  \<372                    0.99               0.98 to 0.99       \<0.0001
  ≥372                     1.00               1.00 to 1.01       0.3487

Abbreviations: CI: confidence interval; OR: odds ratio.
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